Biocompatibles CE-marks embolisation beads:
This article was originally published in Clinica
Executive Summary
Biocompatibles International has CE-marked for sale in Europe its Bead Block embolisation therapy for preventing blood flow to a tumour. The microspheres-based product can provide a minimally invasive alternative to hysterectomy in the treatment of uterine fibroids, says the UK firm. It may also provide a platform for targeted drug delivery. The Farnham, Surrey company has initiated a programme for drug-eluting embolics based on the product which will initially target malignant tumours, such as liver cancer. Bead Block is to be distributed exclusively by Terumo in Europe, Israel and North Africa. It is already approved in the US, where Biocompatibles is seeking approval for the uterine fibroid indication.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.